News

New pre-clinical data were presented in a Late-Breaking Abstract Session at Digestive Disease Week (DDW), held 3 May to 6 May 2014 in Chicago, Illinois. ALN-AAT is one

The investment, which will increase site capacity by more than 20%, comes two years after the company expanded the capacity of its MDI facility in Northridge, California, and

Triglycerides are a type of fat found in blood and an important energy source for the body. According to the company, EPANOVA is the first FDA approved prescription

Selexys develops drugs that target certain underlying mechanisms of inflammatory diseases and cancer. SELK2 is an investigational humanized monoclonal antibody designed to treat Crohn’s Disease and Multiple Myeloma.

The project is aimed at exploring a genetic cause in hereditary forms of the disease as a platform for developing disease-modifying treatment that would slow or stop the

Both the companies have not disclosed the financial details of the agreement, which is for an initial term of three years. Cardiome chief commercial officer Karim Lalji said

Dr. Huib Ovaa is principal investigator of Chemical Biology Laboratories at NKI and a member of FORMA’s deubiquitinase (DUB) investigator network. As part of the deal, FORMA and

Japanese Patent 5443763 claims new pharmaceutical formulations of sapacitabine, while Patent 5457196 claims methods of treating cancer comprising sapacitabine in combination with histone deacetylase (HDAC) inhibitors. According to

With this approval, physicians who treat adults with chronic or accelerated phase CML who are no longer responding to, or who could not tolerate, two or more tyrosine